OR WAIT null SECS
- About Us
- Advertise
- Editorial Information
- Contact Us
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2023 MJH Life Sciences™ and BioPharm International. All rights reserved.
Optimizing a Unique Cancer Vaccine for Intradermal Delivery
Using a hollow microstructured transdermal system to deliver vaccine directly to the dermis.
3M Drug Delivery Systems and Panacea Pharmaceuticals are collaborating to deliver Panacea’s investigational cancer vaccine, PAN- 301-1, directly to the dermis via the 3M hollow microstructured transdermal system (hMTS).
PAN-301-1 vaccine is a biologic that cannot be administered orally, or via a transdermal patch; therefore, it was thought that intradermal delivery to the skin could potentially be the optimal route of administration. The hMTS offers high-volume, reproducible, direct delivery capability to the highly-vascularized dermis.
Download the
.
Article Details
BioPharm International eBook: Development Strategies for Emerging Therapies
Vol. 30
September 2017
Pages: 31-35
Citation
When referring to this article, please cite it as S. Fuller et al., "Optimizing a Unique Cancer Vaccine for Intradermal Delivery, " BioPharm International Development Strategies for Emerging Therapies eBook (September 2017).
Related Content:
